JP6814632B2 - 顆粒球除去方法 - Google Patents
顆粒球除去方法 Download PDFInfo
- Publication number
- JP6814632B2 JP6814632B2 JP2016523462A JP2016523462A JP6814632B2 JP 6814632 B2 JP6814632 B2 JP 6814632B2 JP 2016523462 A JP2016523462 A JP 2016523462A JP 2016523462 A JP2016523462 A JP 2016523462A JP 6814632 B2 JP6814632 B2 JP 6814632B2
- Authority
- JP
- Japan
- Prior art keywords
- body fluid
- cellulose acetate
- granulocytes
- group
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003714 granulocyte Anatomy 0.000 title claims description 94
- 238000000034 method Methods 0.000 title claims description 43
- 229920002301 cellulose acetate Polymers 0.000 claims description 70
- 210000001124 body fluid Anatomy 0.000 claims description 57
- 239000010839 body fluid Substances 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 30
- 210000001185 bone marrow Anatomy 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 22
- 210000005087 mononuclear cell Anatomy 0.000 claims description 17
- 210000005259 peripheral blood Anatomy 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 210000004700 fetal blood Anatomy 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 239000011324 bead Substances 0.000 description 33
- 238000011084 recovery Methods 0.000 description 27
- 210000001616 monocyte Anatomy 0.000 description 26
- 239000000243 solution Substances 0.000 description 22
- 125000006239 protecting group Chemical group 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- -1 benzhydryl group Chemical group 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229920001917 Ficoll Polymers 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229910001021 Ferroalloy Inorganic materials 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000092 effect on stroke Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
置換率(%)=(A−B)F×0.6005/被検物質重量(g)
F:滴定に使用した0.1規定水酸化ナトリウム水溶液のファクター
(1)ブタ骨髄液の調製
体重約30kgの家畜ブタに筋肉注射にてケタラール、セラクタールを注入し、その後ネンブタールを静脈注射にて追加することにより麻酔を行った。10mLのシリンジに約20IU/mLになるように予めヘパリンを入れておき、腸骨より15Gの穿刺針を用いて骨髄液を採取した。次に採取した骨髄プールにヘパリンを最終濃度で50IU/mLになるように添加して、十分に転倒混和を行った後、70μmセルストレーナーを通過させることにより血餅、骨粉などを取り除いた。
(単核球/顆粒球全数)=(用いた骨髄液量)×(白血球濃度)×(単核球/顆粒球画分比率)÷100
酢酸セルロースからなる担体として、国際公開第2006/025371号に記載の酢酸セルロースビーズを用いた。酢酸セルロースビーズを生理食塩液(最終濃度で5IU/mLのヘパリンを含む)に懸濁した。酢酸セルロースビーズのアセチル基による置換率は49%であり、粒子径は約500μmであった。沈降体積で3.5mLの酢酸セルロースビーズをミニカラム(アクリル製、断面積0.79cm2、高さ4.5cm)に充填した。酢酸セルロースビーズ合計表面積は314cm2であった。カラム入口側にポリ塩化ビニル製のチューブ(内径1mm、外径3mm、長さ85cm)を装着し、またカラム出口側にも同様のポリ塩化製ビニル(長さ40cm)を装着した。先に調製した骨髄液をテフロン(登録商標)製三角フラスコ内(内容量50mL、サンワ)に入れ、37℃恒温槽内に静置し、4minに一度、穏やかに攪拌した。次に線速0.11cm/min(骨髄液が酢酸セルロースビーズに接触する時間(以後、接触時間)41分)で通液実験を開始した。カラム出口側から骨髄液が出始めたことを目視で確認した時点を開始時点として、8.2mL採取した。得られた採取液を回収液とした。
(単核球/顆粒球回収数)=(回収液量)×(白血球濃度)×(単核球/顆粒球画分比率)÷100
(単核球回収率(%))=(単核球回収数)÷(単核球全数)×100
(顆粒球除去率(%))=100−(顆粒球回収数)÷(顆粒球全数)×100
線速を0.17cm/min(接触時間27分)に変更した点、及び回収液を10.4mL採取した点以外は、実施例1と同様の操作を行った。単核球回収率は72%であり、顆粒球除去率は94%であった。
ミニカラムの酢酸セルロースビーズ量、酢酸セルロースビーズ合計表面積、及び断面積を、酢酸セルロースビーズ量6.9mL、酢酸セルロースビーズ合計表面積615cm2、断面積1.5cm2に変更した点、線速を0.19cm/min(接触時間24分)に変更した点、及び回収液を40.9mL採取した点以外は、実施例1と同様の操作を行った。単核球回収率は75%であり、顆粒球除去率は95%であった。
線速を0.33cm/min(接触時間13分)に変更した点以外は、実施例2と同様の操作を行った。単核球回収率は60%であり、顆粒球除去率は46%であった。
ミニカラムの酢酸セルロースビーズ量、酢酸セルロースビーズ合計表面積、断面積、及び高さを、酢酸セルロースビーズ量3.7mL、酢酸セルロースビーズ合計表面積329cm2、断面積0.13cm2、高さ28.5cmに変更した点、線速を1.3cm/min(接触時間22分)に変更した点、及び回収液を12.0mL採取した点以外は、実施例1と同様の操作を行った。単核球回収率は84%であり、顆粒球除去率は35%であった。
酢酸セルロースビーズとして、酢酸セルロースをジメチルスルホキシドとプロピレングリコールの混合溶剤に溶解し、この溶液を特開昭63−117039号公報に記載された方法(振動法)により液滴化し、凝固させて得た酢酸セルロースビーズを用いた点、及び回収液を8.3mL採取した点以外は、実施例2と同様の操作を行った。回収液の単核球回収率、及び顆粒球の除去率を求めた。酢酸セルロースビーズのアセチル基による置換率は54%であり、粒子径は約0.5mmであった。単核球回収率は76%であり、顆粒球除去率は91%であった。
酢酸セルロースビーズのアセチル基による置換率を48%に変更した点以外は、実施例2と同様の操作を行った。単核球回収率は69%であり、顆粒球除去率は93%であった。
酢酸セルロースビーズのアセチル基による置換率を43%に変更した点以外は、実施例2と同様の操作を行った。単核球回収率は72%であり、顆粒球除去率は90%であった。
酢酸セルロースビーズのアセチル基による置換率を22%に変更した点以外は、実施例2と同様の操作を行った。単核球回収率は73%であり、顆粒球除去率は86%であった。
酢酸セルロースビーズとして、購入した酢酸セルロースビーズ(adacolumn、JIMRO)を用いた点以外は実施例2と同様の操作を行った。酢酸セルロースビーズのアセチル基による置換率は55%であり、粒子径は2000μmであった。酢酸セルロースビーズ合計表面積は78cm2であった。単核球回収率は81%であり、顆粒球除去率は52%であった。
ミニカラムの酢酸セルロースビーズ量、酢酸セルロースビーズ合計表面積、及び高さを、酢酸セルロースビーズ量1.8mL、酢酸セルロースビーズ合計表面積157cm2、高さ2.3cmに変更した点以外は、実施例2と同様の操作を行った。単核球回収率は69%であり、顆粒球除去率は90%であった。
ミニカラムの酢酸セルロースビーズ量、酢酸セルロースビーズ合計表面積、及び高さを、酢酸セルロースビーズ量7.1mL、酢酸セルロースビーズ合計表面積627cm2、高さ9.0cmに変更した点以外は、実施例2と同様の操作を行った。単核球回収率は62%であり、顆粒球除去率は95%であった。
(1)ブタ骨髄液の調製
実施例1と同様の方法で調製した骨髄液を用いた。
先に調製した骨髄液を2mL用いて、生理食塩液2mLと混合して希釈した。次に、容量15mLの遠沈管(IWAKI)に、Ficoll Paque−Plus(GEヘルスケア)溶液を3mL添加し、該Ficoll溶液の上層に、上述の希釈した骨髄液を重層した。遠心分離機CF7D2(日立製作所)にて、回転数1400rpmで30分間遠心分離することにより、得られた単核球画分層を回収した。Ficoll溶液を除去する目的で、回収した単核球画分層に生理食塩液を10mL添加し、遠心分離機CF7D2にて、回転数1500rpmで10分間遠心分離し、上清を除いた。再度生理食塩液を10mL添加して、回転数1500rpmで10分間遠心分離した。再び上清を除き、生理食塩水を、液量が1mLになるように加えた。
体液をヒト末梢血に変更した点以外は、実施例2と同様の操作を行った。ヒト末梢血は、健常人ボランティアより18Gの注射針を用い上腕部より注意深く採血し、抗凝固剤としてヘパリンを使用し、血液中のヘパリン濃度は5IU/mLとすることにより調製した。単核球回収率は73%であり、顆粒球除去率は92%であった。
体液をウシ末梢血に変更した点以外は、実施例2と同様の操作を行った。ウシ末梢血はジャパン・ラム株式会社より購入し、抗凝固剤としてCPD液(テルモ)を使用し、血液100mLに対するCPD液量は28mLとした。単核球回収率は90%であり、顆粒球除去率は92%であった。
Claims (4)
- (a)流入部と流出部を備え、アセチル基によって置換されている水酸基の割合が全水酸基の23〜54%である酢酸セルロースからなる球状又は粒状の担体を合計表面積が157〜627cm2となるように収容した容器の前記流入部から、体液を0.11cm/min以上0.19cm/min以下の線速で送液する工程、及び
(b)前記流出部から顆粒球濃度が低下した体液を回収する工程
を含む、体液から顆粒球を除去する方法(ただし、体外循環回路に用いる方法を除く)。 - 工程(b)で回収される体液中の顆粒球濃度が、工程(a)で送液される体液中の顆粒球濃度の10%以下である、請求項1に記載の方法。
- 工程(a)で送液される体液が骨髄液、末梢血、又は臍帯血である、請求項1又は2に記載の方法。
- 工程(b)で回収される体液における単核球、幹細胞、造血幹細胞、間葉系幹細胞、及びそれらの混合物からなる群から選択される有核細胞の濃度が、工程(a)で送液される体液における有核細胞の濃度よりも高い、請求項1〜3のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014112321 | 2014-05-30 | ||
JP2014112321 | 2014-05-30 | ||
PCT/JP2015/064713 WO2015182501A1 (ja) | 2014-05-30 | 2015-05-22 | 顆粒球除去方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015182501A1 JPWO2015182501A1 (ja) | 2017-04-20 |
JP6814632B2 true JP6814632B2 (ja) | 2021-01-20 |
Family
ID=54698835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016523462A Active JP6814632B2 (ja) | 2014-05-30 | 2015-05-22 | 顆粒球除去方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6814632B2 (ja) |
WO (1) | WO2015182501A1 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0780062A (ja) * | 1993-09-17 | 1995-03-28 | Asahi Medical Co Ltd | エンドトキシン除去器および浄化血液の製造方法 |
US7850858B2 (en) * | 2004-08-30 | 2010-12-14 | Kaneka Corporation | Granulocyte adsorbent |
-
2015
- 2015-05-22 JP JP2016523462A patent/JP6814632B2/ja active Active
- 2015-05-22 WO PCT/JP2015/064713 patent/WO2015182501A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JPWO2015182501A1 (ja) | 2017-04-20 |
WO2015182501A1 (ja) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7850858B2 (en) | Granulocyte adsorbent | |
JP5975985B2 (ja) | 単核球調製材、及び前記調製材を利用した単核球調製方法 | |
EP2644689A1 (en) | Method and material for separating leukocytes or mononuclear cells | |
JPWO2004018615A1 (ja) | フィブリン含有組成物 | |
JP6143746B2 (ja) | 有核細胞捕捉フィルターまたはこれを利用した有核細胞調製法 | |
JP4949230B2 (ja) | 細胞調製方法および装置 | |
JP6814632B2 (ja) | 顆粒球除去方法 | |
JP4958554B2 (ja) | リンパ球増殖抑制因子の吸着材及び処理方法 | |
JP2004129550A (ja) | 単球の分離回収方法 | |
JP4640991B2 (ja) | 単球選択捕捉材料 | |
JP3938973B2 (ja) | 細胞分離方法 | |
JP4583325B2 (ja) | 吸着材の処理方法 | |
Suaudeau et al. | The Ito “Flow‐Through” Centrifuge A New Device for Long‐Term (24 hours) Plasmapheresis without Platelet Deterioration | |
JP4833443B2 (ja) | 造血幹細胞の採取方法 | |
JP2011010583A (ja) | 液性油成分除去方法、細胞分離方法及び細胞分離キット | |
JPWO2006106763A1 (ja) | リンパ球増殖抑制因子の除去方法 | |
JP4318234B2 (ja) | 単球を分化誘導せしめる方法 | |
JPH10201470A (ja) | 細胞分離方法及び細胞浮遊液 | |
JP2006050976A (ja) | 細胞回収方法 | |
Akande | Macroporous monolithic cryogels for extracorporeal medical devices | |
JP2003210161A (ja) | 肝幹細胞の濃縮器及び肝臓疾患の治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20160912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160912 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191106 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20191106 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20191119 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191220 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200107 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20200124 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20200128 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200714 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201013 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20201027 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20201201 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20201201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6814632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |